Objective

To investigate the expression and clinical significance of Bridging INtegrator 1 (BIN1) and cyclin D2 (CCND2) in newly diagnosed cytogenetically heterogenous adult acute myeloid leukemia patients. Methods Real-time quantitative PCR (RQ-PCR) was used to detect the expression of BIN1 and CCND2 genes in 49 newly diagnosed adult patients with AML, and their clinical significance was analyzed. Results BIN1 and CCND2 genes are highly expressed in patients with AML, which suggest their potential as molecular markers. A statistical significant correlation was found between BIN1 expression with bone marrow blasts (P = 0.012), CD34 expression (P = 0.026), NLR (P = 0.019) and Karyotype risk (P = 0.005). There was a statistically significant correlation between CCND2 and age (P = 0.001), NLR (P = 0.046) Karyotype risk (P = 0.033). The expression level of BIN1 was related to early treatment response (CR or not) (P = 0.043). CCND2 expression was significantly correlated with overall survival (P = 0.013), but not with CR (P = 0.731). Conclusion BIN1 and CCND2 genes are highly expressed in patients with AML, suggesting the potential of these two genes as molecular markers. Moreover, high levels of CCND2 are associated with better prognosis, suggesting the possibility of these two genes as prognostic markers.

中文翻译：

---

BIN1和CCND2基因在成人急性髓系白血病患者中的预后意义

客观的

探讨桥接整合因子1（BIN1）和细胞周期蛋白D2（CCND2）在初诊细胞遗传学异质性成人急性髓系白血病患者中的表达及临床意义。方法采用实时定量PCR（RQ-PCR）检测49例初诊成人AML患者BIN1和CCND2基因的表达情况，并分析其临床意义。结果 BIN1和CCND2基因在 AML 患者中高表达，这表明它们作为分子标记的潜力。BIN1表达与骨髓原始细胞之间存在统计学显着相关性（ P = 0.012）、CD34 表达（P  = 0.026）、NLR（P  = 0.019）和核型风险（P  = 0.005）。CCND2与年龄( P  =0.001)、NLR( P  =0.046)、核型风险( P  =0.033)之间存在统计学上显着的相关性。BIN1表达水平与早期治疗反应（CR与否）相关（P  =0.043）。CCND2表达与总生存率显着相关（P  = 0.013），但与 CR 无关（P  = 0.731）。结论 BIN1和CCND2基因在 AML 患者中高表达，表明这两个基因作为分子标记的潜力。此外，高水平的CCND2与更好的预后相关，表明这两个基因作为预后标志物的可能性。